

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067094 A1

(51) International Patent Classification:

C07D 215/40 (2006.01) C07D 403/12 (2006.01)
C07D 239/94 (2006.01) A61K 31/517 (2006.01)
C07D 401/12 (2006.01) A61P 17/04 (2006.01)

(21) International Application Number:

PCT/US2021/052044

(22) International Filing Date:

24 September 2021 (24.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/083,638 25 September 2020 (25.09.2020) US
63/145,407 03 February 2021 (03.02.2021) US
63/211,987 17 June 2021 (17.06.2021) US

(71) Applicant: **ESCIENT PHARMACEUTICALS, INC.**
[US/US]; 10578 Science Center Drive, Suite 250, San
Diego, California 92121 (US).

(72) Inventors; and

(71) Applicants: **LANIER, Marion** [US/US]; c/o Escient Phar-
maceuticals, Inc., 10578 Science Center Drive, Suite 250,
San Diego, California 92121 (US). **BOEHM, Marcus**
[US/US]; c/o Escient Pharmaceuticals, Inc., 10578 Science
Center Drive, Suite 250, San Diego, California 92121
(US). **HUANG, Liming** [US/US]; c/o Escient Pharmaceu-
ticals, Inc., 10578 Science Center Drive, Suite 250, San
Diego, California 92121 (US). **MARTINBOROUGH, Es-
ther** [US/US]; c/o Escient Pharmaceuticals, Inc., 10578
Science Center Drive, Suite 250, San Diego, California
92121 (US). **SAINZ, Marcos** [US/US]; c/o Escient Phar-
maceuticals, Inc., 10578 Science Center Drive, Suite 250,
San Diego, California 92121 (US). **SELFRIEDGE, Bran-
don** [US/US]; c/o Escient Pharmaceuticals, Inc., 10578
Science Center Drive, Suite 250, San Diego, California
92121 (US). **YEAGER, Adam** [US/US]; c/o Escient Phar-

maceuticals, Inc., 10578 Science Center Drive, Suite 250,
San Diego, California 92121 (US).

(74) Agent: **KHANNA, Hemant** et al.; Seed Intellectual Prop-
erty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seat-
tle, Washington 98104-7064 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS



(57) Abstract: Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R¹, R², R³, R⁴, R⁵, R⁶ and R^x are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

WO 2022/067094 A1